IDO1 and prostate carcinoma: Interestingly, the IDO1 inhibitor lindrodostat had no inhibitory effects on LNCaP-EnzR or PC3 cells (Supplementary Fig. S13a), which was consistent with the finding that prostate cancer cells expressed undetectable levels of IDO1 protein (Fig. 3e).